Science & Technology
Science and Technology
Science and Technology
Mon, June 29, 2009
Sun, June 28, 2009
Sat, June 27, 2009
Fri, June 26, 2009
Thu, June 25, 2009 ChromoCure, Inc.: ChromoCure, Inc. (Formerly Cyberhand Technologies) Releases Spin-Off and Dividend Details
RENO, NV--(Marketwire - June 25, 2009) - ChromoCure, Inc. (formerly Cyberhand) (
Three (3) separate companies will be formed by the spin-offs of ChromoCure (formerly named Cyberhand Technologies).
The first will be under the newly created "CtiWin Group." The new company will consist of the Pocketop keyboard, intellectual property costing over 3 million, and includes the new upcoming Bluetooth model. The Pocketop keyboard was the best selling folding keyboard in the world in Canada, Britain, Japan and the USA in 2001, 2002 and part of 2003. It retailed hundreds of thousands of sales at premier retailers like Radio Shack, Sears, Widget, Good Guys and Costco to name a few.
The second spin-off will be Cyberhand Robotics. The spun-off company will include all of its current intellectual property costing over a million dollars in development and research, including patents and trademarks. Also included is the all new Raptor Controller, the fastest controller available which is 50% faster, more comfortable, and is fully programmable with a completely redesigned key structure that is superior to our initial Black Widow. The new Raptor design comes with a unique feature set simply not available anywhere including an adjustable profile, hard play air flow, an independent LCD setup screen, sure track super play keys and precision engineering to reduce fatigue and eliminate carpal tunnel symptoms.
The third company will be TriEye Design. It will hold all of the property creation and engineering software, hardware and specialists. The value of this asset is estimated to be worth hundreds of thousands of dollars. This company will create the next generation of products for Pocketop, Cyberhand Robotics and many others.
The combination of the three dividends and spin-offs will result in the distribution of common stock, pro rata, to shareholders over the next ninety days. Each company will be obtaining a new CUSIP number for the securities being distributed. All shareholders will retain their existing shares in CYHA.
Neither CYHA nor the new spin-off companies will affect a reverse-split of their stock.
Investors will be timely updated on the following:
-- Full OTC Disclosure procedures and new company name and stock symbol -- Business Plan and Strategies Released for ChromoCure, Inc. -- Appointments to ChromoCure Board of Advisors -- Agreements with technology vendors and co-marketing initiatives -- National campaign to expand the Company's pathology lab partner network
The Company will soon receive a new ticker symbol and its name properly reflected on the OTC market. The exact date for this change will be announced when received from FINRA. Stockholders may trade in ChromoCure stock now under the current symbol and will retain their shares when the ticker and name is changed to properly reflect the company's name. The Company is not performing a reverse or forward split of its stock as part of this ticker and name change procedure.
About ChromoCure
ChromoCure develops and provides cancer detection systems to diagnostic labs. The systems are provided by the Company and installed on a revenue sharing basis. The Company's systems measure the unique genomic characteristic common to all cancers. This characteristic is never found in normal cells. The Company believes its detection technology has an effective accuracy of 100% for all cancers at all stages. The Company also applies its science and technology to non-toxic and non-invasive approaches to cancer therapy and cure research. Visit: [ www.chromocure.com ]
Safe-Harbor Statement
This release contains statements (such as projections of future performance) that are forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those projected as a result of certain risks and uncertainties. The company's website contains various RISK FACTORS (incorporated herein by reference) and should be read before any investment decision.
